Janux stock plunges after hours following mCRPC trial data
Shawn Olsson, Chief Commercial Officer of LENZ Therapeutics, Inc. (NASDAQ:LENZ), sold 10,000 shares of common stock on November 17, 2025, for approximately $261,022.
The sales were executed in two tranches. The first involved 4,212 shares sold at a weighted average price of $25.7385, with prices ranging from $25.12 to $26.11. The second transaction saw 5,788 shares sold at a weighted average price of $26.3669, within a price range of $26.12 to $26.81.
On the same day, Olsson also exercised options to acquire 10,000 shares of LENZ Therapeutics common stock at an exercise price of $2.08 per share, for a total value of $20,800.
In other recent news, LENZ Therapeutics reported its third-quarter 2025 earnings, revealing a significant rise in operating expenses and a net loss per share. This financial update comes despite the successful launch of its new eye drop product, VIZ, which holds promising market potential. The increased expenses appear to have contributed to a negative reaction from investors. Although the product launch was successful, the financial results seem to have overshadowed the positive market reception. Analyst firms have not yet provided updates on their ratings or future expectations for LENZ Therapeutics. The company’s financial performance will likely be a focal point for investors moving forward. These developments highlight the challenges LENZ Therapeutics faces in balancing product innovation with financial stability. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.